AU721121B2 - Inactivation of HIV co-receptors as therapy for HIV infection - Google Patents

Inactivation of HIV co-receptors as therapy for HIV infection Download PDF

Info

Publication number
AU721121B2
AU721121B2 AU53724/98A AU5372498A AU721121B2 AU 721121 B2 AU721121 B2 AU 721121B2 AU 53724/98 A AU53724/98 A AU 53724/98A AU 5372498 A AU5372498 A AU 5372498A AU 721121 B2 AU721121 B2 AU 721121B2
Authority
AU
Australia
Prior art keywords
chemokine
receptor
cell
expression
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU53724/98A
Other languages
English (en)
Other versions
AU5372498A (en
Inventor
Xuefan Bai
Ji-Dai Chen
Si-Yi Chen
An-Gang Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University
Original Assignee
Wake Forest University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University filed Critical Wake Forest University
Publication of AU5372498A publication Critical patent/AU5372498A/en
Application granted granted Critical
Publication of AU721121B2 publication Critical patent/AU721121B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU53724/98A 1996-12-02 1997-12-02 Inactivation of HIV co-receptors as therapy for HIV infection Ceased AU721121B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3227796P 1996-12-02 1996-12-02
US60/032277 1996-12-02
PCT/US1997/022198 WO1998024923A1 (fr) 1996-12-02 1997-12-02 Therapie de l'infection a virus de l'immunodeficience humaine (vih) par inactivation de co-recepteurs du vih

Publications (2)

Publication Number Publication Date
AU5372498A AU5372498A (en) 1998-06-29
AU721121B2 true AU721121B2 (en) 2000-06-22

Family

ID=21864069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53724/98A Ceased AU721121B2 (en) 1996-12-02 1997-12-02 Inactivation of HIV co-receptors as therapy for HIV infection

Country Status (6)

Country Link
EP (1) EP0963441A4 (fr)
JP (1) JP2001505055A (fr)
AU (1) AU721121B2 (fr)
CA (1) CA2273192A1 (fr)
IL (2) IL130160A0 (fr)
WO (1) WO1998024923A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1639009B1 (fr) 2003-05-30 2013-02-27 Merus B.V. Bibliothèque de fragments fab pour préparer un mélange d'anticorps
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69521331T2 (de) * 1994-11-01 2001-09-20 Winfried Wels Nukleinsäure-einbringungssystem
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6214540B1 (en) * 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1

Also Published As

Publication number Publication date
EP0963441A4 (fr) 2002-10-02
WO1998024923A1 (fr) 1998-06-11
IL130160A0 (en) 2000-06-01
CA2273192A1 (fr) 1998-06-11
JP2001505055A (ja) 2001-04-17
IL130160A (en) 2007-07-04
EP0963441A1 (fr) 1999-12-15
AU5372498A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
Chen et al. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy
RU2562868C2 (ru) Двойной вектор для подавления вируса иммунодефицита человека
Watanabe et al. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques
CN109320615B (zh) 靶向新型bcma的嵌合抗原受体及其用途
CN108864286B (zh) 靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途
WO1997005242A1 (fr) Nouveau clone proviral du virus de l'immunodeficience humaine de type 2 (hiv-2) a possibilite de replication, appele hiv-2kr
US6822070B2 (en) Truncated CRAF1 inhibits CD40 signaling
AU721121B2 (en) Inactivation of HIV co-receptors as therapy for HIV infection
EP0903981A1 (fr) Conception de nouveaux systemes d'encapsulation de type vih d'une grande efficacite en vue d'une therapie genique
US5834589A (en) Chimeric viral receptor polypeptides
US20050214258A1 (en) Vectors for delivering viral and oncogenic inhibitors
US6686333B1 (en) Inhibition of HIV replication using soluble Tat peptide analogs
Yang et al. Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes
WO1998014587A1 (fr) Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles
JP3623230B2 (ja) キメラ受容体ポリペプチド，ヒトｈ１３タンパク質，ならびにその使用
AU2003242496B2 (en) Conjugate
WO1993025682A9 (fr) Polypeptides recepteurs mutants, proteines h13 humaines et leurs utilisations
WO1998003669A9 (fr) Vecteurs d'administration d'inhibiteurs de cellules virales et oncogenes
WO1996028189A1 (fr) Gene de fusion transdominant double et proteine
US6953687B1 (en) Vectors for delivering viral and oncogenic inhibitors
WO1999003999A1 (fr) Procedes et compositions servant a inhiber la reaction proinflammatoire
WO2000027198A1 (fr) Vecteurs retroviraux codant l'interferon alpha et utilisations de ces derniers
US7071301B1 (en) Chimeric viral receptor polypeptides, human viral receptor polypeptides and uses thereof
AU774551B2 (en) Vectors for delivering viral and oncogenic inhibitors
WO2004013330A1 (fr) Constructions genetiques multifonctionnelles a capacite d'inhibition elevee de l'expression du ccr5 dans la surface cellulaire

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)